Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

Budget cuts, delays to grant reviews, and layoffs of federal workers at agencies like the NIH and the National Science Foundation have affected nearly every research organization in the US. If ...

Parents will participate in late April with Reverse Rett 2025 to raise funds to battle syndrome afflicting their daughter.

Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements.

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...

CRISPR technology has revolutionised genetic engineering, offering unprecedented precision in DNA editing with vast implications for medicine, agriculture and conservation. Yet, its power demands ...

A team of researchers at Karolinska Institutet has developed a novel tool for genetic research. The study, published in ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

Fintel reports that on March 31, 2025, RBC Capital downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...